



Solution for Tuberculosis Drug Resistance

End-to-end RUO Solution for Mycobacterium Tuberculosis Drug Susceptibility Testing by Sequencing

Suited to Small, Medium & High Throughput Laboratories


A composite image. The left side shows several red, rod-shaped Mycobacterium tuberculosis bacteria against a dark purple background. The right side shows a person's hands holding a tablet device. The screen of the tablet displays a digital version of an XTB assessment report. The report has a header "03-2018 literature review 03-2018". It includes a table with columns for "XTB assessment", "Drugs", and various resistance percentages (15.00%, 10.00%, 3.00%). The drugs listed include Isoniazid, Rifampicin, Rifabutin, Ethambutol, Pyrazinamide, Streptomycin, Isoniazid, Rifampicin, Levofloxacin, Moxifloxacin, Ofloxacin, Amoxicillin, Kanamycin, Capreomycin, Ciprofloxacin, Bedaquiline, Ethionamide, Para-aminosalicylic acid, Cycloserine, and Ethionamide. The report also includes sections for "Interpretations", "For the clinician", "Mutations", and a note about extensively drug-resistant TB.

Solution for Tuberculosis Drug Resistance

End-to-end RUO Solution for *Mycobacterium* Tuberculosis Drug Susceptibility Testing by Sequencing
Suited to Small, Medium & High Throughput Laboratories



Sample Preparation



PCR



NGS Sequencing



Data Analysis



Lab & Data Analysis automation

1st Line

Rifampicin

Isoniazid

Pyrazinamid

Ethambutol

2nd Line

Moxifloxacin
Levofloxacin

Amikacin

Kanamycin

Capreomycin

Streptomycin

Ethionamin

New Drugs

Bedaquilin

Clofazimin



Sample Preparation



PCR



NGS sequencing



NGS data analysis

Sample collection

DNA extraction

Lab self-validate

DeepChek® 13-Plex (RUO)

Library preparation
reagents

Indexes
(24/48/96/384)

DeepChek® NGS Library Preparation (RUO)

Analysis

Reporting

BacterioChek® - TB Software (CE-IVD)

NGS

Turnaround time	~3-4 days
Hands-on-time	~1-3 h

MULTIPLEX AMPLIFICATION DESIGN

- Multiplex in one single tube
- 13 genes



PERFORMANCES

- Heteroresistance: Down to 0.1%
- Sensitivity < 1000 cp/mL (optimization ongoing)
- Validated on various Liquid & Solid Cultures

SEQUENCING


- Validated on iSeq100, MiniSeq, MiSeq (Illumina)
- Validated on S5 + Ion Chef (ThermoFisher)
- Validation on NanoPore MinIon ongoing

EXAMPLE OF REPORT (MULTIPLE PAGES)

- Complete or “One Page” report
- Large analysis panel

BacterioChek® - TB Drug Resistance Determination				
	03-2018 literature review 03-2018			
XTB assessment	15.00% MDR-TB	10.00% MDR-TB	3.00% MDR-TB	
Drugs	15.00%	10.00%	3.00%	
Isoniazid	R	R	R	
	NT upMtbA	g-17	99.44%	37
	AA katG	S315T	99.44%	37
Rifampicin	R	R	R	
	AA rpoB	D459E/coll S18V	99.09%	37
Rifabutin	NA	NA	NA	
Ethambutol	R	R	R	
	AA emtbB	M308I	98.4%	37
Pyrazinamide	S	S	S	
Streptomycin	S	S	S	
Fluoroquinolone	S	S	S	
Levofloxacin	NA	NA	NA	
Moxifloxacin	NA	NA	NA	
Ofoxacin	NA	NA	NA	
Amikacin	R	R	R	
	NT rrs	a3401g	99.58%	37
Kanamycin	R	R	R	
	NT rrs	a3401g	99.58%	37
Capreomycin	R	R	R	
	NT rrs	a3401g	99.58%	37
Linezolid	S	S	S	
Bedaquiline	S	S	S	
Ethionamide	NA	NA	NA	
Para-aminosalicylic acid	NA	NA	NA	
Cycloserine	NA	NA	NA	

Legend				
XTB assessment	MDR-TB	Multidrug resistant TB	XDR-TB	Extensively drug resistant TB
Interpretations	S	Susceptible	R	Resistant
For the selected drug, at least one region impacting drug resistance according to the indicated guideline is not covered, therefore the derived drug resistance assessment cannot be determined				
Mutations	Type	Region	Mutation	Prevalence





References & contact



DeepChek® Assay 13-Plex KB DRUG SUSCEPTIBILITY TESTING V1 (RUO)	128A24
DeepChek Sample Prep KB V1	127A24
BacterioChek® - TB Software (CE-IVD)	S-12-023 (TL)
DeepChek® NGS Clean-up beads (60mL) (RUO)	N411-02
DeepChek® NGS LIBRARY PREPARATION V1 (24 indexes) (RUO)	116A24+124A24
DeepChek® NGS LIBRARY PREPARATION V1 (48 indexes) (RUO)	116A48+124A48
DeepChek® NGS LIBRARY PREPARATION V1 (96 indexes) (RUO)	116A96+124A96
DeepChek® NGS LIBRARY PREPARATION V1 (384 indexes) (RUO)	116A384+124A384



Advanced Biological Laboratories S.A.
52-54 avenue X Septembre, L-2550
Luxembourg, Luxembourg
contact@ablsa.com
<https://www.ablsa.com>
TEL : (+352) 26 38 96 761
FAX : (+352) 26 38 96 76 31